Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10177795 | 0.92 | HRH4 (0.37) | HRH4HRH3POLB | |
| SCHEMBL13884357 | 0.89 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL14433591 | 0.89 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL13884332 | 0.89 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL13884334 | 0.89 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL18025230 | 0.89 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL13884314 | 0.89 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL18591728 | 0.89 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL13884336 | 0.89 | HRH4 (0.39) | HRH4HRH3POLB | |
| SCHEMBL25496890 | 0.82 | HRH4 (0.34) | HRH4HRH3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-29 | — | — | US | disclosed |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230372309-A1 | ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST | KYOTO UNIVERSITY (JP) | 2023-11-23 | — | — | US | disclosed |
| US-11820864-B2 | Aqueous polyglycidol synthesis with ultra-low branching | VANDERBILT UNIVERSITY (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230365610-A1 | Aryl Glucoside Derivative | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20230365610-A1 | Aryl Glucoside Derivative | SHANGHAI ZHEYE BIOTECHNOLOGY CO. LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-11814372-B2 | Agonists of EPHA and their uses | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| US-20090124602-A1 | KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-05-14 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-7338961-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196859-A1 | Novel antibacterial agents | ENGASE, PEPD, PGLS | HRH4 3892/4885HRH3 4322/4885POLB 1367/4885 |
| US-20230372309-A1 | ALPHA-2 ADRENERGIC RECEPTOR ANTAGONIST | ADRA2A, ADRB2, ADRA2B | HRH4 403/4885HRH3 339/4885POLB 1937/4885 |
| US-20090124602-A1 | KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K6 | HRH4 3292/4885HRH3 2990/4885POLB 1396/4885 |
| US-20070134729-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | HRH4 4031/4885HRH3 4422/4885POLB 1148/4885 |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | HRH4 1974/4885HRH3 1358/4885POLB 1740/4885 |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | HRH4 2507/4885HRH3 1915/4885POLB 251/4885 |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | HRH4 1529/4885HRH3 862/4885POLB 2648/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | HRH4 2047/4885HRH3 1415/4885POLB 1926/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | HRH4 3725/4885HRH3 3674/4885POLB 1390/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | HRH4 4457/4885HRH3 4130/4885POLB 2996/4885 |
| US-20240067656-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | KRAS, HRAS, NRAS | HRH4 3699/4885HRH3 2787/4885POLB 1015/4885 |
| US-11814372-B2 | Agonists of EPHA and their uses | EPHA2, EPHA7, EPHA1 | HRH4 1846/4885HRH3 1444/4885POLB 4432/4885 |
| US-11858940-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | HRH4 2677/4885HRH3 2096/4885POLB 3604/4885 |
| US-20230365610-A1 | Aryl Glucoside Derivative | SLC5A1, SLC5A2, SLC10A1 | HRH4 3679/4885HRH3 4320/4885POLB 4575/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | HRH4 4031/4885HRH3 4422/4885POLB 1148/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | HRH4 4031/4885HRH3 4422/4885POLB 1148/4885 |
| US-12016856-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | HRH4 282/4885HRH3 561/4885POLB 3894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.